ClinicalTrials.gg
RecruitingNCT06434194Updated May 18, 2025

Serrantor OCT Study

An interventional study of Serranator PTA Serration Catheter and PTA (Standard of Care) in Critical Limb Ischemia, sponsored by Cagent Vascular LLC. Recruiting at 2 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
31st of 82
60 · median 38
Started
2024
with 5 others
No phase
38 of 105
8 open now
Primary completion
2025-06
later than 4 of 19 live
Registered
101st of 105
by date
Lead sponsor
2 of 105
Cagent Vascular LLC

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 31st largest by planned enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2024, is one of 38 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 101st registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

03

Conditions studied

  • Critical Limb Ischemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rutherford clinical category 4-6 of the target limb
  • Age of subjects is >18 years old
  • Patients has given to participate in this study

Exclusion criteria

Exclusion Criteria:

  • De novo or restenotic (without prior stent) stenosis (≥70%) or occlusion
  • Target lesion is in the BTK arteries, including below the knee popliteal, tibioperoneal trunk, tibial, peroneal, and pedal arteries.
  • Angiographic visual estimated reference vessel diameter is between 2.0 and 5.0 mm.
  • Lesion length less than 220 mm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Serrantor

    Subjects randomized to the Serranator Arm of the study will be treated with the Serranator PTA Serration Balloon

    Device: Serranator PTA Serration Catheter

  • Active comparator
    PTA

    Subjects randomized to the PTA Arm of the study will be treated with a standard of care percutaneous transluminal angioplasty (PTA) balloon.

    Drug: PTA (Standard of Care)

Interventions

  • DeviceSerranator PTA Serration Catheter

    The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.

  • DrugPTA (Standard of Care)

    A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.

06

What researchers measure

Primary outcomes

  1. Residual Lumen Volume Stenosis

    Residual lumen volume stenosis derived by OCT comparing Serration Angioplasty and conventional plain balloon angioplasty (PTA) measured at 10-15min post procedure. The lesion segment is defined as the entire treated segment where the balloon has been inflated.

    Time frame: Baseline

Secondary outcomes

  1. OCT Residual Diameter Stenosis

    Residual stenosis as measured by OCT

    Time frame: Baseline

  2. Angiography Residual Diameter Stenosis

    Residual stenosis as measured by angiography

    Time frame: Baseline

  3. Dissection Pattern

    The incidence of dissection pattern between the study arms as reported by the OCT Corelab. The CoreLab will evaluate OCT images of each dissection including analysis of the length of the dissection, arc of the dissection, number of serrations, and the length of the serration.

    Time frame: Baseline

  4. Correlation of Luminal Gain and Plaque Modification

    The correlation of the plaque modification achieved as determine from the OCT evaluation after treatment with the Study Device to the luminal gain achieved by conventional angioplasty as evaluated by the Core Lab.

    Time frame: Baseline

  5. Rate of Optimal PTA

    Rate of procedures that achieve optimal PTA (\<30% diameter stenosis without flow-limiting dissection measured by angiography)

    Time frame: Baseline

  6. Bail-out Stenting

    Rate of bail-out stenting

    Time frame: Baseline

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 30, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06434194
Lead sponsor
Cagent Vascular LLC
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Oct 31, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
May 18, 2025

Study contacts

Feeny
Contact
kjclinconsulting@gmail.com
4197878496
Wittwer
Contact
twittwer@mededge.io

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion